|
Miltenyi Biotec
cd160 by55 Cd160 By55, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/cd160 by55/product/Miltenyi Biotec Average 92 stars, based on 1 article reviews
cd160 by55 - by Bioz Stars,
2026-05
92/100 stars
|
Buy from Supplier |
|
OriGene
anti cd160 ![]() Anti Cd160, supplied by OriGene, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/anti cd160/product/OriGene Average 94 stars, based on 1 article reviews
anti cd160 - by Bioz Stars,
2026-05
94/100 stars
|
Buy from Supplier |
|
Thermo Fisher
cd160 pe antibody ![]() Cd160 Pe Antibody, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/cd160 pe antibody/product/Thermo Fisher Average 90 stars, based on 1 article reviews
cd160 pe antibody - by Bioz Stars,
2026-05
90/100 stars
|
Buy from Supplier |
|
Miltenyi Biotec
human cd133 ![]() Human Cd133, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/human cd133/product/Miltenyi Biotec Average 92 stars, based on 1 article reviews
human cd133 - by Bioz Stars,
2026-05
92/100 stars
|
Buy from Supplier |
|
Quartett GmbH
polyclonal cd43 antibody 1-cd160 ![]() Polyclonal Cd43 Antibody 1 Cd160, supplied by Quartett GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/polyclonal cd43 antibody 1-cd160/product/Quartett GmbH Average 90 stars, based on 1 article reviews
polyclonal cd43 antibody 1-cd160 - by Bioz Stars,
2026-05
90/100 stars
|
Buy from Supplier |
|
Novus Biologicals
cd160 af700 ![]() Cd160 Af700, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/cd160 af700/product/Novus Biologicals Average 91 stars, based on 1 article reviews
cd160 af700 - by Bioz Stars,
2026-05
91/100 stars
|
Buy from Supplier |
|
Novus Biologicals
90074af700 rrid ab 2941072 clone 275 ![]() 90074af700 Rrid Ab 2941072 Clone 275, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/90074af700 rrid ab 2941072 clone 275/product/Novus Biologicals Average 91 stars, based on 1 article reviews
90074af700 rrid ab 2941072 clone 275 - by Bioz Stars,
2026-05
91/100 stars
|
Buy from Supplier |
|
Novus Biologicals
ch l cd160 af700 novus biologicals cat ![]() Ch L Cd160 Af700 Novus Biologicals Cat, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/ch l cd160 af700 novus biologicals cat/product/Novus Biologicals Average 92 stars, based on 1 article reviews
ch l cd160 af700 novus biologicals cat - by Bioz Stars,
2026-05
92/100 stars
|
Buy from Supplier |
|
Rockland Immunochemicals
nk1 1 pk136 pe cy7 ![]() Nk1 1 Pk136 Pe Cy7, supplied by Rockland Immunochemicals, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/nk1 1 pk136 pe cy7/product/Rockland Immunochemicals Average 91 stars, based on 1 article reviews
nk1 1 pk136 pe cy7 - by Bioz Stars,
2026-05
91/100 stars
|
Buy from Supplier |
Journal: Nature Communications
Article Title: The integrated molecular and histological analysis defines subtypes of esophageal squamous cell carcinoma
doi: 10.1038/s41467-024-53164-x
Figure Lengend Snippet: a The immune cell infiltration profiling across our cohort is shown, clustered by the level of estimated immune cell infiltration. Each row represents an immune cell type as estimated by the method used by Danaher et al. Immune cells are natural killer (NK) cells, neutrophils, B cells, macrophages, CD4 + mature cells, regulatory T cells (Treg), CD56dim NK cells, total T cells (T cells), CD8 + T cells, cytotoxic cells, exhausted CD8 + T cells (exhausted CD8), dendritic cells (DC) and mast cells. Consensus clustering was performed. Each column represents a patient sample. Three immune infiltration clusters were identified: C1, C2 and C3. b Levels of gene expression of XCL1 and XCL2 for n = 120 samples are shown among the three immune subtypes as a box and whisker plot. Significance in each pairwise comparison is shown using the two-sided Wilcoxon rank-sum test. c IHC analysis revealed that the C2 immune subtype had significantly increased levels of CD8 (67 samples) and CD56 (75 samples) expression. Significance was determined using a two-sided Wilcoxon test; * p < 0.05, *** p < 0.001. d The survival analysis of all profiled immune cell types against overall survival for 102 samples is shown. The hazard ratio (HR) derived from the multivariate Cox regression model is shown as a whisker plot. The blue square indicates the HR value, and the error bars represent 95% confidence intervals. Significance is determined using a two-sided log-rank test (■ p < 0.1; * p < 0.05). e A Kaplan–Meier curve is shown for NK cell estimates against overall survival for our cohort (China, 102 samples) and TCGA (90 samples). Multivariant survival analysis was performed for the China cohort. HR and p -value derived from the log-rank test are shown. f The number of cases of the four transcriptomic subtypes is shown among the three immune subtypes C1, C2 and C3. Fisher´s exact test was used to test if there is any difference in the proportion of transcriptomic subtypes between different immune subtypes (**** p < 0.0001). g The scatter plot of expression levels between LGR6 and three NK cell markers, XCL1 , XCL2 and CD160 , is shown. Two-sided Pearson’s correlation coefficient and associated p -value are displayed. h IHC (Immunohistochemistry) staining of XCL1 and LGR6 from one patient, Sample 427, and IHC of CD160 and LGR6 from a different patient, Sample 341, are shown. The IHC results show that XCL1 and LGR6 , CD160 and LGR6 are co-expressed in tumour cells. Furthermore, to provide a more comprehensive understanding of our findings, we included a larger visualisation of IHC results depicting CD160, LGR6, XCL1, and CD56 in both normal control and tumour samples for Sample 333 in Supplementary Fig. . In b , c , the box bounds the interquartile range divided by the median, with the whiskers extending to a maximum of 1.5 times the interquartile range beyond the box. Source data are provided as a Source Data file.
Article Snippet: Antibodies used in this study were listed as follows, anti-SFRP1 (1:200, Atlas antibodies, HPA064870), anti-XCL1 (1:400, Atlas antibodies, HPA057725), anti-LGR6 (1:100, Abcam,126747),
Techniques: Expressing, Whisker Assay, Comparison, Derivative Assay, Immunohistochemistry, Staining, Control
Journal: Nature Communications
Article Title: The integrated molecular and histological analysis defines subtypes of esophageal squamous cell carcinoma
doi: 10.1038/s41467-024-53164-x
Figure Lengend Snippet: a GSEA normalised enrichment score (NES) of EP300 Mut (mutated) versus Wt (wildtype) samples (green bars) and EP300 high versus low expression samples (red bars), against representative (upregulated) gene sets of four transcriptomic subtypes and upregulated genes in XCL -high ESCC cell lines (XCL_up). The values of FDR were shown within the bars. b GSEA plots of ‘stemness_up’ and ‘differentiated_up’ gene sets for the EP300 Mut (mutated) versus Wt (wildtype) comparison, and the ‘stemness_up’ and ‘XCL1_up’ gene sets for the EP300 high versus low-expression comparison. FDR q -values were shown. c Gene expression of CD160 between EP300 mutated and wildtype samples. Wilcoxon rank-sum test was used to compare the level between groups. d Pathway functional mutation enrichment adjusted for tumour mutation burden and the correlation between functional mutation enrichment ratio and tumour cellularity are plotted together for each hallmark gene set. P -values derived from the Kruskal–Wallis test comparing the enrichment ratio among the four subtypes were used for y -axis values. For significant hallmark gene sets, they were coloured to represent the subtype which had the highest enrichment for this gene set. e Significance P -values (−log10 transformed) comparing the enrichment scores among the four subtypes against P -values comparing GSVA values among the four subgroups are plotted for each hallmark gene set. For significant hallmark gene sets that passed both significance thresholds ( P < 0.05), they were coloured to represent the subtype which had the highest enrichment for that gene set in both functional mutation and pathway expression levels. f The intra-tumour heterogeneity for 102 samples, measured as the Shannon density, is shown across the four transcriptomic and immune subtypes, using the Wilcoxon rank-sum test. g The survival analysis of the Shannon density index against overall survival is shown using a multivariate analysis. The P -value derived from the log-rank test was shown, along with the hazard ratio and 95% confidence interval. All significance is shown in the figure, * P < 0.05, ** P < 0.01, and **** P < 0.0001. In c , f , the box bounds the interquartile range divided by the median, with the whiskers extending to a maximum of 1.5 times the interquartile range beyond the box. Source data are provided as a Source Data file.
Article Snippet: Antibodies used in this study were listed as follows, anti-SFRP1 (1:200, Atlas antibodies, HPA064870), anti-XCL1 (1:400, Atlas antibodies, HPA057725), anti-LGR6 (1:100, Abcam,126747),
Techniques: Expressing, Comparison, Functional Assay, Mutagenesis, Derivative Assay, Transformation Assay
Journal: Cell reports
Article Title: Multimodal profiling of term human decidua demonstrates immune adaptations with pregravid obesity
doi: 10.1016/j.celrep.2023.112769
Figure Lengend Snippet: KEY RESOURCES TABLE
Article Snippet: CD160-AF700 ,
Techniques: Luminex, Recombinant, Red Blood Cell Lysis, Staining, Translocation Assay, Flow Cytometry, Sequencing, Software